SELANK

Selank is a synthetic analog of the immunomodulatory peptide tuftsin, consisting of the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. In Russian clinical trials for anxiety disorders and neurasthenia, intranasal Selank produced anxiolytic effects comparable to benzodiazepines while also providing anti-asthenic (energy-boosting) benefits without sedative side effects or dependence potential^[1][2]. Preclinical studies in primates demonstrated that intranasal Selank eliminated fear and anxiety behaviors with long-term stabilizing effects on neurobehavior^[4]. Rodent studies confirmed robust anxiolytic efficacy comparable to classical tranquilizers^[5]. While most published human data utilized intranasal dosing (the original formulation), subcutaneous administration has shown effectiveness in research settings with consistent absorption and ease of dose measurement^[3]. A 14-day continuous course was well-tolerated and effective in human trials^[2], and even high-dose applications have been explored for conditions such as attenuating opioid withdrawal symptoms in animal models^[5].

Observations from clinical and preclinical literature.

• Produces anxiolytic effects comparable to benzodiazepines in human clinical trials without sedation or dependence risk^[1].
• Provides anti-asthenic (energy-boosting) benefits alongside anxiety reduction^[2].
• Induces lasting neurobehavioral changes; primate studies showed elimination of fear/anxiety behaviors with long-term stabilizing effects^[4].
• Generally well tolerated in clinical studies; a 14-day continuous course was well-tolerated and effective in human trials^[2].
• Occasional mild injection-site reactions (redness, minor irritation) may occur with subcutaneous administration; proper site rotation minimizes this risk.
• Lacks sedative side effects typical of classical anxiolytics, allowing for daytime use without impairment^[1].
• Has been explored at higher doses for experimental applications such as attenuating opioid withdrawal symptoms, indicating a wide therapeutic range^[5].

Complementary strategies for optimal cognitive and anxiolytic outcomes.

• Maintain consistent sleep hygiene and aim for 7–9 hours of quality sleep to support neurological function and stress resilience.
• Incorporate regular physical activity; both aerobic exercise and resistance training support mood regulation and cognitive performance.
• Practice stress-management techniques such as mindfulness, meditation, or breathwork to complement Selank’s anxiolytic effects.
• Support nutritional status with adequate protein, omega-3 fatty acids, and micronutrients essential for neurotransmitter synthesis.
• Minimize alcohol and stimulant use, which can interfere with anxiety management and neurological stability.

• PubMedClinical trial of Selank for generalized anxiety disorder (intranasal, human study)
• PubMedSelank for neurasthenia: 14-day clinical trial demonstrating anxiolytic and anti-asthenic effects (human study)
• Hindawi BioMed ResearchIntranasal Selank administration review: neurobehavioral effects and clinical applications (review article)
• SpringerPrimate studies: intranasal Selank eliminates anxiety behaviors with long-term effects (preclinical)
• SpringerSelank attenuates opioid withdrawal symptoms in animal models (preclinical dosing study)
• CDCVaccine administration best practices: subcutaneous injection technique and site selection
• Cleveland ClinicSubcutaneous injection guide: technique, sites, and rotation principles
• NCBI BookshelfClinical procedures: injection preparation, aseptic technique, and administration standards
• CDCInjection safety guidelines: single-use devices, sharps disposal, and preventing unsafe practices
• NIBSCPeptide storage guidelines: lyophilized and reconstituted stability considerations
• PMCPharmacologic review: subcutaneous drug delivery and absorption considerations